L&L Bio Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
2ndary - Private
- Investors
-
6
L&L Bio General Information
Description
Developer of biomacromolecule drugs designed for tumor immunotherapy. The company offers bispecific antibodies, trispecific antibody platforms, and monoclonal antibody drugs, thereby providing clinical research centers and cancer patients with specialized hardware and biological platforms for targeted immunotherapy and drug-resistant cancer treatment.
Contact Information
Website
www.lnlbio.comCorporate Office
- Room 306, 3rd Floor, Building 1
- Number 39 Qiyuan Road, Qianwan New District
- Ningbo, Zhejiang 315336
- China
Corporate Office
- Room 306, 3rd Floor, Building 1
- Number 39 Qiyuan Road, Qianwan New District
- Ningbo, Zhejiang 315336
- China
L&L Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Secondary Transaction - Private | 06-Nov-2026 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Private | 29-Jul-2026 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series B2) | 01-Dec-2025 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B) | 15-Mar-2023 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series A) | 07-May-2021 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 23-Jul-2019 | Completed | Generating Revenue | |||
| 1. Corporate | 25-Apr-2018 | Completed | Generating Revenue |
L&L Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
L&L Bio Patents
L&L Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024159984-A1 | Trispecific antibody technology platform and use thereof | Inactive | 01-Feb-2023 | ||
| WO-2023125561-A1 | Tigit-targeting antibody, bispecific antibody and application thereof | Inactive | 27-Dec-2021 | ||
| WO-2021185273-A1 | Sirpα-targeting antibody or antigen binding fragment thereof, and preparation and application thereof | Inactive | 20-Mar-2020 | ||
| WO-2020249041-A1 | Antibody and bispecific antibody targeting lag-3 and use thereof | Inactive | 13-Jun-2019 | ||
| WO-2020007240-A1 | Bispecific antibody and use thereof | Inactive | 03-Jul-2018 | C07K16/2803 |
L&L Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
L&L Bio Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Huayi Brothers Media | Corporation | Minority | ||
| Shenzhen Dongfang Huisheng Capital Management | Corporation | Minority | ||
| Hongfeng Capital | Growth/Expansion | Minority | ||
| Panlin Capital | Venture Capital | Minority | ||
| Qiaojing Capital | Venture Capital | Minority |
L&L Bio FAQs
-
When was L&L Bio founded?
L&L Bio was founded in 2015.
-
Where is L&L Bio headquartered?
L&L Bio is headquartered in Ningbo, China.
-
What is the size of L&L Bio?
L&L Bio has 9 total employees.
-
What industry is L&L Bio in?
L&L Bio’s primary industry is Drug Discovery.
-
Is L&L Bio a private or public company?
L&L Bio is a Private company.
-
What is L&L Bio’s current revenue?
The current revenue for L&L Bio is .
-
Who are L&L Bio’s investors?
Huayi Brothers Media, Shenzhen Dongfang Huisheng Capital Management, Hongfeng Capital, Panlin Capital, and Qiaojing Capital are 5 of 6 investors who have invested in L&L Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
